Prof J Gordon McVie MD, FRCP, FRCPS, FRCES, FMedSci, DSc (Hon)is the Chairman of ORIL’s Scientific Advisory Committee . Professor McVie was formerly Director General of the Cancer Research Campaign in the UK before it merged with the Imperial Cancer Research Foundation to form Cancer research UK, when he became co-Director General. Professor McVie is a leading world authority in the research and treatment of cancer, having trialled over 80 new chemical entities in the clinic.
Professor McVie is currently Senior Consultant at the Scientific Directorate within the European Institute of Oncology, Milan and Director of Cancer Intelligence, which provides advisory services to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is visiting professor at Glasgow University and honorary consultant in medical oncology at the Welsh Cancer Institute, Cardiff.
Prof Giaccone a major role in the European Organization for Research and Treatment of Cancer (EORTC), serving as a member of the EORTC’s Lung Cancer Cooperative Group since 1982 and as its Chair from 1993 to 2000. In January 2013 he joined the Lombardi Comprehensive Cancer Center at Georgetown University, Washington DC as the Associate Director for Clinical Research and the Director of Clinical Research for the MedStar Health Cancer Network’s Washington Region, where he is currently based. He has published more than 500 peer-reviewed papers and contributed to more than 30 book chapters.
Dr Michael J Story BE(Hons), PhD(Cantab)Dr Story has over 35 years experience with the pharmaceutical industry including 13 years with FH Faulding & Co Limited (now Halcygen), where he held a range of positions covering product development, marketing and manufacturing, before managing the R&D division for 6 years. He introduced new innovative technology and formulation skills to Faulding, which led to the highly successful international commercialisation of products based on these technologies. Dr Story founded his pharmaceutical consulting company, Story Pharmaceutics Pty Ltd, in 1991.
Dr Story has played a leading role in the science of ORIL’s compounds to their current position, resulting in the filing of four patents; he is co-inventor. Dr Story’s ongoing input to the understanding of the science and therapeutic mode of action of ORIL’s compounds, and his experience in commercialising pharmaceutical products, is essential to the continued progress of ORIL.
Dr Felquer holds a PhD in molecular biology and a MBA in entrepreneurship. He joined the Company in March 2013 and brings many years of scientific research and executive management within the pharmaceutical industry. Over the past 15 years Dr Felquer has been involved in cancer research in both academia and industry. In 2008 he joined the Adelaide-based oncology Contract Research Organization vivoPharm as the Head of the in vitro laboratory where he introduced over 30 new cell and molecular biology techniques. He then moved to the role of Vice-president, Business development where his work was instrumental in the establishment of the company’s American research facility in central Pennsylvania. In 2011 Dr Felquer founded Innovate Industry Services, an Innovation and Business Development consulting firm.
Dr Philip A Marshall BSc(Hons), PhD, FRACI, CChem, MAICDis Chief Executive Officer and Director. Dr Marshall manages the corporate aspects of the Company, as well as the scientific and research programs. Dr Marshall’s skills and training cover synthetic organic and medicinal chemistry, pharmaceutical science, compliance and regulatory affairs. In 1991 he founded his consultancy company, Pharmchem Technical Services Pty Ltd, which has provided independent advice to over 130 companies in Europe, South Africa, the Americas and throughout Asia-Pacific. From 2004-06, he was also General Manager, Scientific Affairs at Sigma Pharmaceuticals, where he had executive responsibility over the company’s 6 Australian sites for R&D strategic planning, quality, regulatory affairs and technical due diligence in acquisitions, whilst overseeing 180 scientific staff.
Dr K Michael Wayteis Company Secretary and Director. Dr Wayte was full time CEO of ORIL from 2003 to 2008 and is a major shareholder. He was diagnosed with bowel cancer in 1986. After following a demanding and restrictive vegetarian diet with specific plant-based therapies he recovered and is alive and well today. As a result of his recovery he founded ORIL in 1993 with the objective of researching plant-based therapies for cancer.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia